Literature DB >> 23640439

Accuracy of Doppler echocardiography in the assessment of pulmonary arterial hypertension in patients with congenital heart disease.

B Wang1, Y Feng, L-Q Jia, X-L Wu, D-D Li, H-X Zhou, J Yang, B-M Liang, L Wang, K-J Cui, H Huang, Q Yi.   

Abstract

BACKGROUND AND OBJECTIVES: Pulmonary arterial hypertension (PAH) is a major cause of morbidity and mortality among patients with congenital heart disease (CHD). Earlier diagnosis of PAH would be of great benefit for the estimation of the CHD, the grasp of the indications for surgery and prognosis. PATIENTS AND METHODS: We assessed the diagnostic accuracy of Doppler echocardiography (D-ECHO) in detecting PAH in patients with CHD and the value of estimation about ventricular morphology and function of PAH-CHD patients. 123 CHD patients evaluated for suspected PAH were prospectively recruited. D-ECHO was performed and estimated right ventricular systolic pressure (RVSP) was measured to screen for PAH. Subsequently, pulmonary hemodynamic parameters were measured by right heart catheterization (RHC) for definitive diagnosis of PAH.
RESULTS: RHC identified 66/123 (54%) patients with PAH. The noninvasive cut-point was: estimated right ventricular systolic pressure (RVSP) > 36.5 mm Hg by D-ECHO. D-ECHO classified 107 subjects correctly (sensitivity 89.4%, specificity 84.2%). The area under receiver-operating characteristic curve (AUC) was 0.96 for D-ECHO. A positive significant correlation (r = 0.853, p < 0.01) was found between RVSP measured by D-ECHO and systolic pulmonary arterial pressure (sPAP) measured by RHC. In addition, D-ECHO showed higher RVSP, left ventricular internal diameter (LV), right atrial diameter (RA), right ventricular internal diameter (RV), left ventricular end-diastolic diameter (EDD), left ventricular diastolic end-diastolic volume (EDV) and mitral velocity A wave (AMV) values in the PAH-CHD group than in the CHD group (p < 0.05).
CONCLUSIONS: D-ECHO is not only an important noninvasive diagnostic technique for PAH-CHD patients, but also a tool which can indicate the ventricular remodeling and diastolic dysfunction induced by PAH to some extent.

Entities:  

Mesh:

Year:  2013        PMID: 23640439

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

Review 1.  Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults.

Authors:  Yasushi Tsujimoto; Junji Kumasawa; Sayaka Shimizu; Yoshio Nakano; Yuki Kataoka; Hiraku Tsujimoto; Michihiko Kono; Shinji Okabayashi; Haruki Imura; Takahiro Mizuta
Journal:  Cochrane Database Syst Rev       Date:  2022-05-09

Review 2.  Advanced imaging tools rather than hemodynamics should be the primary approach for diagnosing, following, and managing pulmonary arterial hypertension.

Authors:  Mario Gerges; Christian Gerges; Irene M Lang
Journal:  Can J Cardiol       Date:  2015-01-28       Impact factor: 5.223

3.  Comparison of Pulmonary Artery Pressure Measurement With Doppler Echocardiography or With Right Heart Catheterization in Patients With Congenital Heart Disease.

Authors:  Dan Yin; Ying Wang; Min Zheng; Huijing Wei; Mi Li; Tiewei Lv; Yonghong Bai; Jie Tian; Xiaoyun Wu
Journal:  Front Pediatr       Date:  2019-10-18       Impact factor: 3.418

4.  Sensitivity and Specificity of Pulmonary Artery Pressure Measurement in Echocardiography and Correlation with Right Heart Catheterization.

Authors:  Muhammad Adil Soofi; Muhammad Azam Shah; Ammar Mohammed AlQadhi; Abdullah Mofareh AlAnazi; Waleed M Alshehri; Amir Umair
Journal:  J Saudi Heart Assoc       Date:  2021-08-30

5.  Automated 3D Volumetry of the Pulmonary Arteries based on Magnetic Resonance Angiography Has Potential for Predicting Pulmonary Hypertension.

Authors:  Fabian Rengier; Stefan Wörz; Claudius Melzig; Sebastian Ley; Christian Fink; Nicola Benjamin; Sasan Partovi; Hendrik von Tengg-Kobligk; Karl Rohr; Hans-Ulrich Kauczor; Ekkehard Grünig
Journal:  PLoS One       Date:  2016-09-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.